Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03500874
Other study ID # HAI-CRCLM-ADJUVANT
Secondary ID
Status Terminated
Phase Phase 3
First received
Last updated
Start date May 28, 2018
Est. completion date August 31, 2021

Study information

Verified date January 2024
Source Sun Yat-sen University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

HARVEST is an investigator-initiated prospective randomized controlled study comparing adjuvant intravenous systemic chemotherapy with or without HAI- floxuridine (FUDR) in CRC patients post-liver metastasectomy.


Description:

Numerous retrospective studies have indicated a positive synergistic effect of combining adjuvant oxaliplatin/irinotecan-based doublet systemic chemotherapy and hepatic arterial infusion (HAI) for colorectal cancer (CRC) patients following colorectal cancer liver metastases (CRLM) resection. However, this strategy has not been evaluated prospectively to date. HARVEST is an investigator-initiated prospective randomized controlled study comparing adjuvant intravenous systemic chemotherapy with or without HAI- floxuridine (FUDR) in CRC patients post-liver metastasectomy.


Recruitment information / eligibility

Status Terminated
Enrollment 92
Est. completion date August 31, 2021
Est. primary completion date August 31, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. The primary lesion has undergone or is capable of radical resection, and liver metastases can undergo R0/R1 resection (including intraoperative interventional ablation therapy), and postoperative achievement of no evidence of disease (NED). 2. Histologically confirmed colorectal adenocarcinoma 3. Radiologically or pathologically confirmed diagnosis of colorectal liver metastasis 4. No previous surgery, interventional ablation, hepatic arterial infusion (HAI), radiotherapy, or transarterial chemoembolization (TACE) for liver metastases. 5. CT, MRI, or PET/CT (if necessary) confirmed no extrahepatic metastasis. 6. Normal hematologic function (platelets > 90×10^9/L; white blood cells > 3×10^9/L; neutrophils > 1.5×10^9/L). 7. No ascites, normal coagulation function, albumin = 35g/L. 8. Liver function graded as Child-Pugh class A. 9. Serum bilirubin = 1.5 times the upper limit of normal (ULN), transaminases = 5 times ULN, alkaline phosphatase = 2.5 ULN. 10. Serum creatinine below the upper limit of normal (ULN), or calculated creatinine clearance > 50ml/min (using Cockcroft-Gault formula). 11. ECOG performance status of 0-2 12. Life expectancy = 3 months 13. Patients have provided a signed Informed Consent Form 14. Willing and able to undergo follow-up until death or the end of the study or study termination. Exclusion Criteria: 1. Have had any extrahepatic metastasis after being diagnosed with colorectal cancer. 2. Previous surgery, interventional ablation, hepatic arterial infusion (HAI), radiotherapy, or transarterial chemoembolization (TACE) for liver metastases. 3. Liver metastases intended for interventional ablation treatment only. 4. Presence of hepatic artery vascular variation identified by CTA examination, making HAI implantation unsuitable. 5. Severe arterial embolism or ascites. 6. Bleeding tendency or coagulation disorders. 7. Hypertensive crisis or hypertensive encephalopathy. 8. Severe uncontrollable systemic complications such as infection or diabetes. 9. Clinically significant cardiovascular diseases such as cerebrovascular accidents (in the last 6 months before enrollment), myocardial infarction (in the last 6 months before enrollment), uncontrolled hypertension despite appropriate drug treatment, unstable angina, congestive heart failure (NYHA 2-4), and arrhythmias requiring medication. 10. History of or physical examination indicating central nervous system diseases (such as primary brain tumors, uncontrollable epilepsy, any brain metastasis, or history of stroke). 11. Had any other malignant tumors in the past 5 years (excluding basal cell carcinoma and/or cervical carcinoma in situ after radical surgery). 12. Received any investigational drug treatment in the last 28 days before the study. 13. Any residual toxicity from previous chemotherapy (excluding alopecia), such as peripheral neuropathy = NCI CTC v3.0 grade 2, makes the use of a treatment regimen containing oxaliplatin not considered. 14. Allergic to any drugs in the study. 15. Pregnant or lactating women who are not using or refuse to use effective non-hormonal contraception (intrauterine device, barrier contraception combined with spermicidal gel, or sterilization) in women of childbearing age (last menstrual period < 2 years ago) or fertile men who cannot or do not wish to comply with the study protocol. 16. Presence of any other diseases, functional impairment due to metastatic lesions, or suspicious findings in the physical examination suggesting contraindications to the use of the investigational drug or placing the patient at a high risk of treatment-related complications.

Study Design


Intervention

Drug:
FUDR
Floxuridine(FUDR) 0.12 mg/kg/day,on Day 1-14 through the HAI pump.
Oxaliplatin
Oxaliplatin 180 mg/m2 IV over 90 minutes on Day 1, 15.
Leucovorin
Leucovorin 200mg/m2 ivd over 2 hours on Day 1
5FU
5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1.
Irinotecan
Irinotecan 180mg/m2

Locations

Country Name City State
China Sun Yat-sen University Cancer Center Guangzhou Guangdong

Sponsors (1)

Lead Sponsor Collaborator
Sun Yat-sen University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Serum ctDNA methylation levels The methylation status of blood ctDNA at a specific time point (e.g., postoperatively) was considered positive if either of the two markers (SEPT9 and NPY) yielded results above zero. Conversely, it was deemed negative if both markers showed an absence of methylation. Up to 5 years
Primary 3 Year Relapse Free Survival Rate Calculated from the time of liver metastasectomy to the time of recurrence or death, whichever came first or censored at the date of the last follow-up for recurrence-free patients that were still alive up to 36 months
Secondary Overall Survival From date of randomization until the date of death from any cause, assessed up to 5 years up to 5 years
Secondary Treatment-related adverse events Number of patients with adverse events and severity measured according to the NCI CTC 3.0 criteria Up to 36 months
Secondary Liver-specific RFS Measure of the time period during which a patient remains free from the recurrence of liver-related events Up to 36 months
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Completed NCT00098787 - Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05425940 - Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer Phase 3
Suspended NCT04595604 - Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery. N/A
Completed NCT03414125 - Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening N/A
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Recruiting NCT03874026 - Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT03167125 - Participatory Research to Advance Colon Cancer Prevention N/A
Completed NCT03181334 - The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation N/A
Recruiting NCT04258137 - Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study N/A
Recruiting NCT05568420 - A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
Recruiting NCT02972541 - Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer N/A
Completed NCT02876224 - Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors Phase 1
Completed NCT01943500 - Collection of Blood Specimens for Circulating Tumor Cell Analysis N/A